OneLax MaxTussin delivers 200mg guaifenesin per dose, a mucolytic expectorant facilitating airway mucus hydration and rheological modification to promote productive cough and bronchial clearance during acute respiratory infections. The non-sedating liquid formulation enables daytime administration without cognitive or psychomotor impairment, maintaining functional capacity during symptomatic management of viral upper respiratory tract infections and influenza-associated bronchitis. The guaifenesin mechanism enhances mucociliary clearance through increased sputum hydration, reducing mucus viscosity and facilitating expectoration of retained secretions obstructing lower airway patency. The 8 oz liquid volume provides extended treatment duration across multiple doses, supporting sustained symptom management throughout acute illness episodes. The maximum-strength formulation addresses severe chest congestion and productive cough syndromes requiring robust expectorant activity without antihistamine or antitussive components that may impair clearance mechanisms. This evidence-based expectorant therapy represents a practical adjunct to supportive care protocols for individuals experiencing acute respiratory congestion requiring enhanced mucus mobilization and airway clearance optimization.